Recruiting
Phase 2
Phase 3

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Sponsor:

Sutro Biopharma, Inc.

Code:

NCT05870748

Conditions

Ovarian Cancer

Epithelial Ovarian Cancer

Fallopian Tube Cancer

Primary Peritoneal Cancer

Platinum-resistant Ovarian Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Luveltamab tazevibulin

Pegfilgrastim

Gemcitabine

Paclitaxel

Pegylated liposomal doxorubicin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information